Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS
· Delayed Price · Currency is USD
28.35
0.00 (0.00%)
Jul 2, 2025, 4:00 PM EDT
TKPHF Revenue
In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T JPY with 7.45% growth. Takeda Pharmaceutical Company had revenue of 1.05T in the quarter ending March 31, 2025, with 0.24% growth.
Revenue
4,581.55B JPY
Revenue Growth
+7.45%
P/S Ratio
1.57
Revenue / Employee
96.55M JPY
Employees
47,455
Market Cap
47.98B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 84.04M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Takeda Pharmaceutical Company News
- 5 days ago - Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire
- 10 days ago - Takeda Announces New Assignments of Directors - Financial Post
- 10 days ago - Takeda Announces New Assignments of Directors - Business Wire
- 4 weeks ago - European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD - Business Wire
- 4 weeks ago - Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Business Wire
- 5 weeks ago - Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award - Business Wire
- 7 weeks ago - The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 - Business Wire
- 7 weeks ago - Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise - Seeking Alpha